Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medicine for preventing and treating sicca syndrome and composition thereof

A technology for Sjögren's syndrome and drugs, which is applied in the direction of drug combinations, pharmaceutical formulas, and medical preparations containing active ingredients. It can solve problems such as low stability, adverse reactions, and limited antioxidant capacity, and achieve reduced usage, The effect of reducing side effects and small dosage

Active Publication Date: 2017-08-04
NANJING SHUPENG BIOTECH CO LTD
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] The technical problem to be solved in the present invention is exactly the defect existing in the method for above-mentioned existing drug cure SS, and the stability that the medicine VitD of known antioxidant treatment SS, NAC deposit is not high, antioxidant ability is limited, needs larger The dose can guarantee the efficacy and the resulting adverse reactions and other issues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for preventing and treating sicca syndrome and composition thereof
  • Medicine for preventing and treating sicca syndrome and composition thereof
  • Medicine for preventing and treating sicca syndrome and composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Embodiment 1: PQQ prevents and treats Sjögren's syndrome in experimental animals

[0045] method

[0046] Model: NOD mouse model. NOD (Nonobese Diabetes) mice are a genetically deficient animal model of spontaneous diabetes. This kind of female mice began to develop diabetes from 14 weeks, and the incidence rate could be as high as 80% by 30 weeks. NOD mice are also an animal model of Sjogren's syndrome. The submandibular gland of the mice began to infiltrate with inflammatory cells from the age of 12 weeks, accompanied by an increase in the expression of various inflammatory factors. From the age of 16 to 20 weeks, the secretion of saliva decreased and the concentration of salivary salt increased.

[0047]Experimental grouping: 8-week-old female NOD mice were purchased from Shanghai Slack Experimental Animal Company, and divided into control group, active vitamin d group, PQQ group and PQQ combined with active vitamin d, a total of four different treatment groups, 10...

Embodiment 2

[0057] Example 2: PQQ inhibits the activation of NF-κB

[0058] method:

[0059] Activation of NF-κB in mouse submandibular gland tissues detected by Western Blot

[0060] Take the same amount of total protein for each sample, add 4X SDS loading buffer according to the ratio of protein sample: 4X SDS: 3:1, mix well, boil in boiling water at 95°C for 5 minutes; prepare 10% separating gel and 5% stacking gel Carry out SDS-PAGE electrophoresis, transfer membrane, block PVDF membrane with TBST solution containing 5% skim milk at room temperature for 1h or overnight at 4°C; dilute antibody with blocking solution, incubate at room temperature for 2h or overnight at 4°C; wash membrane, incubate with secondary antibody, and then Wash the membrane, mix the A and B liquids in the luminescence kit in a medium volume container, and evenly drop the mixed liquid on the PVDF membrane, and react in the dark for 3-5 minutes.

[0061] result:

[0062] After treatment to 36 weeks, the submand...

Embodiment 3

[0063] Example 3: PQQ and active vitamin D synergistically inhibit the expression levels of inflammatory factors in tissues

[0064] method:

[0065] The submandibular gland tissue of experimental mice was taken, RNA was extracted with Trizol, reverse-transcribed by Superscript III, and reacted at 42°C for 30 minutes. Oligo dT and Random Hexamer were used as primers for reverse transcription. Realtime quantitative PCR reaction system: 2×PCRpremix 10μl, Primers 0.8μl, cDNA 1μl, H20 filling volume 20μl; reaction conditions: 95°C for 10min, 95°C for 15s, 60°C for 60s, plate reading, a total of 50 cycles; melting curve analysis : Temperature 55°C-95°C, read once per minute. Three replicate wells were set up for each sample.

[0066] result:

[0067] Quantitative PCR was used to analyze the expression levels of inflammatory factors in the submandibular gland tissue of mice, and it was found that PQQ treatment for 36 weeks could significantly inhibit the expression levels of infl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to pyrroloquinoline quinine, derivatives and / or salts thereof and application to preparation of medicines for treating and / or preventing primary sicca syndrome, secondary sicca syndrome and mouth dryness, eye dryness and damage of multiple systems caused by fatigue of other exocrine glands and other organs outside glands thereof as well as a medicine composition of PQQ or PQQ combined active vitamins d, NAC, resveratrol, epigallocatechin gallate, curcumin, anthocyanin, vitamin E, vitamin C or vitamin D and the like. The medicine and the medicine composition can be used for treating sicca syndrome and adaptation diseases related to the sicca syndrome. The medicine and the medicine composition are capable of removing excess oxygen radicals in the body, inhibiting NF-kB activation caused by oxidative stress and inhibiting autoimmunity so as to reduce the inflammatory response of the sicca syndrome.

Description

technical field [0001] The present invention relates to the use of pyrroloquinoline quinone, its derivatives and / or salts in Sjögren's syndrome and pharmaceutical compositions, in particular to the use of pyrroloquinoline quinone, its derivatives and / or salts in the preparation of treatments and / or The application of drugs for the prevention of Sjögren's syndrome, dry mouth, dry eyes, and involvement of other exocrine glands and other organs outside the glands caused by Sjögren's syndrome. Background technique [0002] Sjogren's syndrome (SS) is a chronic inflammatory autoimmune disease mainly involving exocrine glands. The inflammatory response is mainly manifested in the epithelial cells of the exocrine glands. Clinically, in addition to salivary glands and lacrimal glands being damaged, resulting in dry mouth and dry eyes, other exocrine glands and other organs outside the glands are involved, resulting in symptoms of multi-system damage. Multiple autoantibodies and hyp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4745A61P1/02A61P27/04
CPCA61K31/4745A61P1/02A61P27/02A61K45/06A61K31/593A61P37/02A61K2300/00
Inventor 温传俊
Owner NANJING SHUPENG BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com